Month: November 2022

Pasqualetto, Gaia; Brancale, Andrea; Young, Mark T. published an article in 2018, the title of the article was The molecular determinants of small-molecule ligand binding at P2X receptors.Synthetic Route of 1428327-31-4 And the article contains the following content:

P2X receptors are trimeric eukaryotic ATP-gated cation channels. Extracellular ATP-their physiol. ligand-is released as a neurotransmitter and in conditions of cell damage such as inflammation, and substantial evidence implicates P2X receptors in diseases including neuropathic pain, cancer, and arthritis. In 2009, the first P2X crystal structure, Danio rerio P2X4 in the apo- state, was published, and this was followed in 2012 by the ATP-bound structure. These structures transformed our understanding of the conformational changes induced by ATP binding and the mechanism of ligand specificity, and enabled homol. modeling of mammalian P2X receptors for ligand docking and rational design of receptor modulators. P2X receptors are attractive drug targets, and a wide array of potent, subtype-selective modulators (mostly antagonists) have been developed. In 2016, crystal structures of human P2X3 in complex with the competitive antagonists TNP-ATP and A-317491, and Ailuropoda melanoleuca P2X7 in complex with a series of allosteric antagonists were published, giving fascinating insights into the mechanism of channel antagonism. In this article we not only summarize current understanding of small-mol. modulator binding at P2X receptors, but also use this information in combination with previously published structure-function data and mol. docking experiments, to hypothesize a role for the dorsal fin loop region in differential ATP potency, and describe novel, testable binding conformations for both the semi-selective synthetic P2X7 agonist 2′-(3′)-O-(4-benzoyl)benzoyl ATP (BzATP), and the P2X4-selective pos. allosteric modulator ivermectin. We find that the distal benzoyl group of BzATP lies in close proximity to Lys-127, a residue previously implicated in BzATP binding to P2X7, potentially explaining the increased potency of BzATP at rat P2X7 receptors. We also present mol. docking of ivermectin to rat P2X4 receptors, illustrating a plausible binding conformation between the first and second transmembrane domains which not only tallies with previous mutagenesis studies, but would also likely have the effect of stabilizing the open channel structure, consistent with the mode of action of this pos. allosteric modulator. From our docking simulations and anal. of sequence homol. we propose a series of mutations likely to confer ivermectin sensitivity to human P2X1. The experimental process involved the reaction of N-((4-(4-Phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide(cas: 1428327-31-4).Synthetic Route of 1428327-31-4

The Article related to mol determinants small mol ligand binding receptor, p2x, ion channel, ligand binding, molecular modeling, structure-function, Pharmacology: Effects Of Inflammation Inhibitors and Immune Agents and other aspects.Synthetic Route of 1428327-31-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On June 27, 2013, Fauber, Benjamin; Rene, Olivier published a patent.Formula: C13H16N2O2 The title of the patent was Preparation of benzylsulfonamide derivatives as RORγ modulators for treatment of arthritis. And the patent contained the following:

The title compounds I [m = 0-4; n = 0-2; X1-4 = N or CRa, wherein Ra = independently H, cyano, C1-5 alkyl, etc.; R1 = independently C1-6 alkyl, halo, C1-6 alkoxy, etc.; R2 = C1-6 alkyl, C3-6 cycloalkyl, C3-6 cycloalkyl-C1-6 alkyl, etc.; R3a-3b, R4a-4b= independently H or C1-6 alkyl; A = P1, P2 or NR11R12; wherein Y = CR13 or N; Z = O, S(O)x, CR14R15, or NR16; Q = CH2, CO, C(O)NH, etc.; p = 1 or 2; q = 1-3; x = 0-2; Rb, R14 = H, C1-6 alkyl or halo; Rc = H, C1-6 alkyl, halo, etc.; R11, R13 = H or C1-6 alkyl; R12 = C1-6 alkyl, C3-6 cycloalkyl or C3-6 cycloalkyl-C1-6 alkyl; R15 = H, C1-6 alkyl, C3-6 cycloalkyl, etc.; R16 = H, C1-6 alkyl, C3-6 cycloalkyl, etc.] or pharmaceutically acceptable salts thereof were prepared Compounds I are retinoid-related orphan receptor gamma (RORγ) modulators and useful for treatment of inflammatory diseases such as arthritis. Compound II was prepared in a multi-step synthesis and displayed IC50 of 0.006 μM for RORc affinity. The experimental process involved the reaction of 4-(4-Acetylpiperazin-1-yl)benzaldehyde(cas: 890092-19-0).Formula: C13H16N2O2

The Article related to benzylsulfonamide preparation ror gamma modulator arthritis treatment, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Others and other aspects.Formula: C13H16N2O2

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On October 31, 1994, Morissey, I.; Smith, J. T. published an article.Electric Literature of 86393-32-0 The title of the article was Activity of 4-quinolones against Pseudomonas aeruginosa. And the article contained the following:

The min. inhibitory concentrations (MICs), bactericidal activities and mechanisms of action of ofloxacin (CAS 82419-36-1), levofloxacin (CAS 100986-85-4) and ciprofloxacin (CAS 86393-32-0) were investigated against Pseudomonas aeruginosa. All three 4-quinolones were found to possess higher MICs against Pseudomonas aeruginosa than against other Gram-neg. bacteria. Despite this, however, all three drugs were more rapidly bactericidal and produced a greater level of kill against Pseudomonas aeruginosa than against any other bacterial species previously tested. Furthermore, MIC tests showed ciprofloxacin to be more potent than ofloxacin or levofloxacin against Pseudomonas aeruginosa. However, bactericidal tests showed levofloxacin to be about 10 times more bactericidal than either ciprofloxacin or ofloxacin. Thus, MIC tests cannot predict the relative bactericidal potency of 4-quinolones against Pseudomonas aeruginosa. Therefore, MIC tests should not be used as the sole measure for the efficacy of 4-quinolones, as is often the case. Surprisingly, the characteristic biphasic dose response curve, normally shown by 4-quinolones against other bacteria, was absent when Pseudomonas aeruginosa was tested. This unusual effect was explained by the presence of bactericidal mechanism A at high 4-quinolone concentrations This loss of bactericidal mechanism A may explain the recent high incidences of chromosomally mediated 4-quinolone resistance with Pseudomonas aeruginosa because it may be easier for Pseudomonas aeruginosa to mutate to resist one mechanism of action than to mutate to resist two or more mechanisms of action. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Electric Literature of 86393-32-0

The Article related to quinolone sensitivity pseudomonas, Microbial, Algal, and Fungal Biochemistry: Antimicrobial Sensitivity and other aspects.Electric Literature of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Abbas, Hosna Hasan; Al Mosawy, Karrar Kadim published an article in 2020, the title of the article was Overview of chronic myeloid leukemia patients in the holy city of Karbala.Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile And the article contains the following content:

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized by presence of Philadelphia chromosome. Over time CML treatment has change dramatically; especially when Tyrosine Kinase Inhibitor (TKI) introduced, which significantly increase survival and improve quality of life for all patients especially when its associated with good drug adherence and sequential response monitoring to TKI. To study the characteristics of CML patient’s in the Holy City of Karbala and the outcome of Tyrosine Kinase Inhibitor in control of their disease. The present descriptive study included 56 patients, conducted in Al Imam Al Hussein Hematol./Oncol. center at the Holy city of Karbala in Iraq from June 2017 – June 2018. Data from patients with CML were collected and critically analyzed for the demog. data, type of treatment they used and their compliance to drug. The median age was 46 years; male-to-female ratio was 1.24:1. 96.4% patients were diagnosed in chronic phase of their disease. Major mol. response achieved in 79% (27/34) of patients on Gleevec. 37.5% patients were switch to Tasigna after Imatinib resistant or intolerance, 52% of them achieved major mol. response. Drug adherence found in 68% (38/56) patients. CML slightly male predominance, diagnosed at age younger than that report in the United States and Europe, response to TKI nearly similar to that report in international study. Drug adherence and sequential monitoring of patients can improve therapeutic effect of TKI therapy. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to chronic myeloid leukemia patients holy city karbala, Pharmacology: Effects Of Cardiovascular, Hematologic, and Renal Drugs and other aspects.Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 31, 2020, Hochhaus, Andreas; Gambacorti-Passerini, Carlo; Abboud, Camille; Gjertsen, Bjoern Tore; Bruemmendorf, Tim H.; Smith, B. Douglas; Ernst, Thomas; Giraldo-Castellano, Pilar; Olsson-Stroemberg, Ulla; Saussele, Susanne; Bardy-Bouxin, Nathalie; Viqueira, Andrea; Leip, Eric; Russell-Smith, T. Alexander; Leone, Jocelyn; Rosti, Gianantonio; Watts, Justin; Giles, Francis J.; on behalf of the BYOND Study Investigators published an article.Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile The title of the article was Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. And the article contained the following:

Bosutinib is approved for newly diagnosed Philadelphia chromosome-pos. (Ph+) chronic phase (CP) chronic myeloid leukemia (CML) and for Ph+ CP, accelerated (AP), or blast (BP) phase CML after prior treatment with tyrosine kinase inhibitors (TKIs). In the ongoing phase 4 BYOND study (NCT02228382), 163 CML patients resistant/intolerant to prior TKIs (n = 156 Ph+ CP CML, n = 4 Ph+ AP CML, n = 3 Ph-neg./BCR-ABL1+ CML) received bosutinib 500 mg once daily (starting dose). As of ≥1 yr after last enrolled patient (median treatment duration 23.7 mo), 56.4% of Ph+ CP CML patients remained on bosutinib. Primary endpoint of cumulative confirmed major cytogenetic response (MCyR) rate by 1 yr was 75.8% in Ph+ CP CML patients after one or two prior TKIs and 62.2% after three prior TKIs. Cumulative complete cytogenetic response (CCyR) and major mol. response (MMR) rates by 1 yr were 80.6% and 70.5%, resp., in Ph+ CP CML patients overall. No patient progressed to AP/BP on treatment. Across all patients, the most common treatment-emergent adverse events were diarrhea (87.7%), nausea (39.9%), and vomiting (32.5%). The majority of patients had confirmed MCyR by 1 yr and MMR by 1 yr, further supporting bosutinib use for Ph+ CP CML patients resistant/intolerant to prior TKIs. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to human bosutinib chronic myeloid leukemia pretreatment, Pharmacology: Effects Of Cardiovascular, Hematologic, and Renal Drugs and other aspects.Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On May 31, 2021, Valencia, Hugo J.; de Aguiar, Mara C. A. M.; Costa, Mariana A.; Mendonca, Diogo C.; Reis, Erik V.; Arias, Nidia E. C.; Drumond, Betania P.; Bonjardim, Claudio A. published an article.Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile The title of the article was Evaluation of kinase inhibitors as potential therapeutics for flavivirus infections. And the article contained the following:

The recent introduction of Zika virus (ZIKV), the recurrence of dengue virus (DENV), and the lethality of yellow fever virus (YFV) have had a significant impact on Brazilian society and public health. Here, we targeted two cellular kinases implicated in cell proliferation and cancer that are also important for viral replication: mitogen-activated protein kinase kinase (MEK) and Src. We used two MEK inhibitors – trametinib and selumetinib – and two Src inhibitors – saracatinib and bosutinib – to inhibit ZIKV, DENV, and YFV replication in cell culture. The cytotoxicity of the four inhibitors was determined by the observation of abnormal morphol. and quantification of adherent cells by crystal violet staining. The antiviral activity of these drugs was assessed based on the reduction of plaque-forming units in cell culture as evidence of the inhibition of the replication of the selected flaviviruses. All four inhibitors showed antiviral activity, but among them, trametinib was the safest and most efficacious against all of the viruses, inhibiting the replication of ZIKV and YFV by 1000-fold, and DENV2/3 by nearly 100-fold. This pan-antiviral effect shows that trametinib could be repurposed for the treatment of flaviviral infections. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to mek src kinase inhibitor therapeutics flavivirus infection, Pharmacology: Other (All Agents and Effects Not Otherwise Assignable) and other aspects.Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On February 29, 2020, Shinoda, Kazunobu; Morita, Shinya; Tamaki, Satoshi; Takahashi, Ryohei; Kitaoka, Sotaro; Asanuma, Hiroshi; Yoshida, Tadashi; Okayama, Mikio; Kasahara, Hidenori; Okamoto, Shinichiro; Oya, Mototsugu published an article.Name: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile The title of the article was Successful Treatment of End-stage Renal Disease in a Patient With Chronic Myeloid Leukemia by Kidney Transplantation and Tyrosine Kinase Inhibitors: A Case Report. And the article contained the following:

Consensus regarding kidney transplantation feasibility in patients with chronic myeloid leukemia (CML) well controlled by tyrosine kinase inhibitors has not yet been achieved. Here, we report a patient with CML well controlled by tyrosine kinase inhibitors who developed end-stage renal disease during treatment and underwent kidney transplantation. CML activity has been carefully and successfully controlled for 4 years post-transplant. Very cautious dose adjustment and temporary cessation of nilotinib were required because kidney function fluctuated in reference to the doses of nilotinib. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Name: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to tki renal disease chronic myeloid leukemia kidney transplantation human, Pharmacology: Effects Of Cardiovascular, Hematologic, and Renal Drugs and other aspects.Name: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On January 31, 2022, Balboa Ramilo, Amanda; Becirovic-Agic, Mediha; Petri, Marcelo Heron; Mani, Kevin; Wanhainen, Anders; Waagsaeter, Dick published an article.SDS of cas: 380843-75-4 The title of the article was The tyrosine kinase inhibitor Bosutinib does not inhibit angiotensin II-induced abdominal aortic aneurysm: Validation of the importance of PDGFR and c-Kit tyrosine kinases by Imatinib. And the article contained the following:

Validation of the importance of PDGFR and c-Kit tyrosine kinases by imatinib. All experiments were approved by the Animal Experiments Ethical Committee in Uppsala. Mice were divided into four groups. One group of control mice (n =8) was infused with Ringer’s solution In the other three groups, aneurysm was induced by infusion of 1000 ng/kg/min of AngII. AngII-infused animals were treated with vehicle (n = 20), 10 mg/kg of Bosutinib (Bos, Cat.number S1014, Selleckchem, TX, USA) (n = 20) or 100 mg/kg of Bosutinib (n = 10) by oral gavage, for 22 days. Control animals also received vehicle by oral gavage. On the last day of the experiment, an abdominal ultrasound (Vevo 1100 ultrasound, VisualSonics) was performed for measurement of aortic diameter Control animals had an average aortic diameter of 1.2 ± 0.108 mm. Aneurysm was defned as an aortic diameter equal or superior to 1.8 mm (1.5-fold increase relative to control). These results indicate that treatment of AngII-induced mice with Bosutinib, in a similar dose to Imatinib or higher, does not have an effect on AAA development. This confirms that inhibition of the PDGFR and/or c-Kit is necessary for the effect of Imatinib on abdominal aortic aneurysm development. Thus, drugs inhibiting c-Kit and PDGFR should be of more interest to test in the context of abdominal aortic aneurysm. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).SDS of cas: 380843-75-4

The Article related to abdominal aortic aneurysm pdgfr ckit tyrosine kinase imatinib, aneurysm, inhibitor, rupture, tyrosine kinase, Pharmacology: Effects Of Cardiovascular, Hematologic, and Renal Drugs and other aspects.SDS of cas: 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 31, 2020, Petzer, Andreas L.; Sperr, Wolfgang R.; Buxhofer-Ausch, Veronika; Sliwa, Thamer; Schmidt, Stefan; Greil, Richard; Woelfler, Albert; Pichler, Petra; Dormann, Clemens; Burgstaller, Sonja; Tinchon, Christoph; Lang, Alois; Goebel, Florian; Uthman, Shanow; Muenchmeier, Niklas; Valent, Peter published an article.COA of Formula: C26H29Cl2N5O3 The title of the article was A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting – R-Effect study. And the article contained the following:

Methods: The Retrospective Evaluation of Early response in CML for long-term Treatment outcome (R-Effect), a multicenter, retrospective chart review, documented patients with newly diagnosed CML-CP starting first-line TKI therapy in routine clin. practice. The primary aim was to assess the 5-yr overall survival rate. Results: Of the 211 patients from 12 centers across Austria (Jan. 2004-May 2010), 176 (median age, 56 years) were included in the anal. All patients received first-line therapy with imatinib. Overall, 136 patients (77.3%) achieved ETR (ETR+ group), whereas 40 (22.7%) did not reach ETR (ETR- group). The ETR+ group had higher 5-yr overall survival (92.5% vs. 77.5%, P = 0.018) and progression-free survival (95.6% vs. 87.5%, P = 0.06) rates compared with the ETR- group. As expected, more patients in the ETR- group were switched to another TKI. At the last contact, 120 patients were still on imatinib and 44 had switched to another TKI (25 to nilotinib, 15 to dasatinib, and 4 to bosutinib). Conclusion: The data are in line with randomized trials demonstrating that ETR is associated with improved survival and thus confirmed these results in patients treated in daily clin. routine. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).COA of Formula: C26H29Cl2N5O3

The Article related to chronic myeloid leukemia therapy, chronic myeloiud leukemia, chronic phase, clinical routine, retrospective evaluation, tyrosine kinase inhibitors, Pharmacology: Effects Of Cardiovascular, Hematologic, and Renal Drugs and other aspects.COA of Formula: C26H29Cl2N5O3

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Mulas, Olga; Caocci, Giovanni; Mola, Brunella; La Nasa, Giorgio published an article in 2021, the title of the article was Arterial hypertension and tyrosine kinase inhibitors in chronic myeloid leukemia: a systematic review and meta-analysis.Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile And the article contains the following content:

Off-target effects in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs) are associated with cardiovascular toxicity. Hypertension represents an important cardiovascular complication and, if not appropriately managed, can contribute to developing thrombotic events. Third-generation TKI ponatinib is associated with hypertension development, and its use is more restricted than in the past. Few data are reported for second-generation TKI, nilotinib, dasatinib, and bosutinib. The aim of this article was to evaluate with a systematic review and meta-anal. the real incidence of hypertension in CML patients treated with second- or third-generation TKI. The PubMed database, Web of Science, Scopus, and ClinicalTrials.gov were systematically searched for studies published between Jan. 1, 2000, and Jan. 30, 2021; the following terms were entered in the database queries: Cardiovascular, Chronic Myeloid Leukemia, CML, Tyrosine kinases inhibitor, TKI, and Hypertension. The study was carried out according to the Preferred Reporting Items for Systematic and Meta-Analyses (PRISMA) statement. A pooled anal. of hypertension incidence was 10% for all new-generation TKI, with an even higher prevalence with ponatinib (17%). The comparison with the first-generation imatinib confirmed that nilotinib was associated with a significantly increased risk of hypertension (RR 2; 95% CI; 1.39-2.88, I2 = 0%, z = 3.73, p = 0.0002). The greatest risk was found with ponatinib (RR 9.21; 95% CI; 2.86-29.66, z = 3.72, p = 0.0002). Hypertension is a common cardiovascular complication in CML patients treated with second- or third-generation TKI. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to arterial hypertension tyrosine kinase inhibitor chronic myeloid leukemia metaanalysis, cardiovascular, chronic myeloid, hypertension, leukemia, tyrosine kinase inhibitor, Pharmacology: Other (All Agents and Effects Not Otherwise Assignable) and other aspects.Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics